礼来
LLY748.190USD
-7.200-0.95%
收盘 09/15, 16:00（美东）报价延迟15分钟
708.41B总市值
51.33市盈率 TTM
关于 礼来 公司
礼来公司是全球知名的创新药物巨头，专注于在人用医药领域的研发、制造与销售。其糖尿病、肥胖及心脏代谢线代表药品含 Basaglar、Humalog、Mounjaro、Trulicity 与 Zepbound（体重管理）；肿瘤产品涵盖 Alimta、Retevmo、Tyvyt、Verzenio；免疫学阵容包含 Ebglyss、Olumiant、Omvoh、Taltz；神经科学线提供 Cymbalta、Emgality；其他重点品牌及疗法尚有 Cialis、Forteo。公司透过 POINT Biopharma 深耕放射性药物研发，并开发 α4β7 抑制剂 MORF-057 治疗 IBD，同时投资 AI 药物设计与数字临床平台以加速候选药上市。
公司简介
公司代码LLY
公司名称Eli Lilly and Co
上市日期Jul 09, 1970
CEOMr. David A. (Dave) Ricks
员工数量47000
证券类型Ordinary Share
年结日Jul 09
公司地址Lilly Corporate Ctr
城市INDIANAPOLIS
上市交易所NYSE Consolidated
国家United States of America
邮编46285
电话13172762000
网址https://www.lilly.com/
公司代码LLY
上市日期Jul 09, 1970
CEOMr. David A. (Dave) Ricks
公司高管
名称
名称/职务
职务
持股
持股变动
Mr. J. Erik Fyrwald
Mr. J. Erik Fyrwald
Independent Director
Independent Director
74.32K
+2.17%
Ms. Anne E. White
Ms. Anne E. White
Executive Vice President, President - Lilly Neuroscience
Executive Vice President, President - Lilly Neuroscience
74.21K
+13.18%
Mr. Patrik Jonsson
Mr. Patrik Jonsson
Executive Vice President, President of Lilly Cardiometabolic Health and President, Lilly USA
Executive Vice President, President of Lilly Cardiometabolic Health and President, Lilly USA
54.13K
+20.12%
Mr. Edgardo Hernandez
Mr. Edgardo Hernandez
Executive Vice President, President - Manufacturing Operations
Executive Vice President, President - Manufacturing Operations
39.73K
-0.04%
Mr. Ilya Yuffa
Mr. Ilya Yuffa
Executive Vice President, President of Lilly International
Executive Vice President, President of Lilly International
26.26K
-4.54%
Ms. Anat Hakim
Ms. Anat Hakim
Executive Vice President, General Counsel, Secretary
Executive Vice President, General Counsel, Secretary
25.66K
-41.06%
Dr. Katherine Baicker, Ph.D.
Dr. Katherine Baicker, Ph.D.
Independent Director
Independent Director
23.16K
+0.62%
Mr. Diogo Rau
Mr. Diogo Rau
Executive Vice President, Chief Information and Digital Officer
Executive Vice President, Chief Information and Digital Officer
19.72K
+77.63%
Mr. Lucas E. Montarce
Mr. Lucas E. Montarce
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
14.69K
+5.12%
Mr. Eric Dozier
Mr. Eric Dozier
Executive Vice President, Chief People Officer
Executive Vice President, Chief People Officer
9.84K
+15.72%
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. J. Erik Fyrwald
Mr. J. Erik Fyrwald
Independent Director
Independent Director
74.32K
+2.17%
Ms. Anne E. White
Ms. Anne E. White
Executive Vice President, President - Lilly Neuroscience
Executive Vice President, President - Lilly Neuroscience
74.21K
+13.18%
Mr. Patrik Jonsson
Mr. Patrik Jonsson
Executive Vice President, President of Lilly Cardiometabolic Health and President, Lilly USA
Executive Vice President, President of Lilly Cardiometabolic Health and President, Lilly USA
54.13K
+20.12%
Mr. Edgardo Hernandez
Mr. Edgardo Hernandez
Executive Vice President, President - Manufacturing Operations
Executive Vice President, President - Manufacturing Operations
39.73K
-0.04%
Mr. Ilya Yuffa
Mr. Ilya Yuffa
Executive Vice President, President of Lilly International
Executive Vice President, President of Lilly International
26.26K
-4.54%
Ms. Anat Hakim
Ms. Anat Hakim
Executive Vice President, General Counsel, Secretary
Executive Vice President, General Counsel, Secretary
25.66K
-41.06%
收入明细
单位: USD更新时间: 7月6日 周日
单位: USD更新时间: 7月6日 周日
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
业务USD
名称
营收
占比
Diabetes-Mounjaro
3.84B
30.18%
Diabetes-Zepbound
2.31B
18.16%
Oncology-Verzenio
1.16B
9.10%
Diabetes-Trulicity
1.10B
8.60%
Diabetes-Jardiance
1.01B
7.97%
其他
3.31B
25.98%
地区USD
名称
营收
占比
U.S.
8.49B
66.70%
Europe
2.39B
18.77%
Other foreign countries
997.40M
7.84%
China
450.80M
3.54%
Japan
402.20M
3.16%
业务
地区
业务USD
名称
营收
占比
Diabetes-Mounjaro
3.84B
30.18%
Diabetes-Zepbound
2.31B
18.16%
Oncology-Verzenio
1.16B
9.10%
Diabetes-Trulicity
1.10B
8.60%
Diabetes-Jardiance
1.01B
7.97%
其他
3.31B
25.98%
股东统计
更新时间: 5月16日 周五
更新时间: 5月16日 周五
持股股东
股东类型
持股股东
持股股东
占比
Lilly Endowment, Inc.
10.12%
The Vanguard Group, Inc.
8.46%
PNC Investments LLC
5.40%
BlackRock Institutional Trust Company, N.A.
4.36%
State Street Global Advisors (US)
3.65%
其他
68.02%
持股股东
持股股东
占比
Lilly Endowment, Inc.
10.12%
The Vanguard Group, Inc.
8.46%
PNC Investments LLC
5.40%
BlackRock Institutional Trust Company, N.A.
4.36%
State Street Global Advisors (US)
3.65%
其他
68.02%
股东类型
持股股东
占比
Investment Advisor
45.59%
Investment Advisor/Hedge Fund
18.56%
Foundation
10.12%
Research Firm
1.97%
Pension Fund
1.91%
Bank and Trust
1.89%
Insurance Company
1.48%
Sovereign Wealth Fund
1.29%
Hedge Fund
0.92%
其他
16.27%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
5717
798.76M
84.28%
+2.87M
2025Q1
5710
800.38M
84.44%
+5.04M
2024Q4
5528
795.43M
83.87%
+627.51K
2024Q3
5177
793.57M
83.49%
-5.03M
2024Q2
5068
795.80M
83.72%
-2.01M
2024Q1
4916
795.04M
83.62%
-6.22M
2023Q4
4670
799.46M
84.21%
-2.37M
2023Q3
4354
800.21M
84.30%
-1.19M
2023Q2
4197
799.48M
84.22%
-4.32M
2023Q1
4061
801.36M
84.15%
-9.39M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Lilly Endowment, Inc.
96.02M
10.13%
-220.00K
-0.23%
Mar 31, 2025
The Vanguard Group, Inc.
78.87M
8.32%
+4.97M
+6.73%
Mar 31, 2025
PNC Investments LLC
51.09M
5.39%
+1.95K
+0.00%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
41.47M
4.38%
+359.58K
+0.87%
Mar 31, 2025
State Street Global Advisors (US)
34.44M
3.63%
+124.04K
+0.36%
Mar 31, 2025
Fidelity Management & Research Company LLC
27.18M
2.87%
-2.17M
-7.40%
Mar 31, 2025
Capital Research Global Investors
15.75M
1.66%
+4.99M
+46.39%
Mar 31, 2025
Geode Capital Management, L.L.C.
18.53M
1.95%
+1.14M
+6.58%
Mar 31, 2025
Capital World Investors
18.38M
1.94%
-1.17M
-5.98%
Mar 31, 2025
T. Rowe Price Associates, Inc.
17.98M
1.9%
-1.75M
-8.89%
Mar 31, 2025
查看更多
持股ETF
更新时间: 8月6日 周三
更新时间: 8月6日 周三
机构名称
占比
Defiance Daily Target 2X Long LLY ETF
84.88%
iShares U.S. Pharmaceuticals ETF
20.57%
Harbor Health Care ETF
16.13%
Roundhill GLP-1 & Weight Loss ETF
15.57%
VanEck Pharmaceutical ETF
13.65%
Amplify Weight Loss Drug & Treatment ETF
12.82%
Proshares Ultra Health Care
12.54%
Health Care Select Sector SPDR Fund
12.53%
iShares U.S. Healthcare ETF
12.33%
Fidelity MSCI Health Care Index ETF
11.06%
查看更多
Defiance Daily Target 2X Long LLY ETF
占比84.88%
iShares U.S. Pharmaceuticals ETF
占比20.57%
Harbor Health Care ETF
占比16.13%
Roundhill GLP-1 & Weight Loss ETF
占比15.57%
VanEck Pharmaceutical ETF
占比13.65%
Amplify Weight Loss Drug & Treatment ETF
占比12.82%
Proshares Ultra Health Care
占比12.54%
Health Care Select Sector SPDR Fund
占比12.53%
iShares U.S. Healthcare ETF
占比12.33%
Fidelity MSCI Health Care Index ETF
占比11.06%
分红派息
近5年累计派现
18.06B
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
Dec 09, 2024
LLY.NB Interim Cash Dividend of gross USD 1.5 paid on Mar 10, 2025 going ex on Feb 14, 2025
Feb 14, 2025
Mar 10, 2025
Feb 14, 2025
Oct 28, 2024
LLY.NB Final Cash Dividend of gross USD 1.3 paid on Dec 10, 2024 going ex on Nov 15, 2024
Nov 15, 2024
Dec 10, 2024
Nov 15, 2024
Jun 24, 2024
LLY.NB Interim Cash Dividend of gross USD 1.3 paid on Sep 10, 2024 going ex on Aug 15, 2024
Aug 15, 2024
Sep 10, 2024
Aug 15, 2024
May 06, 2024
LLY.NB Interim Cash Dividend of gross USD 1.3 paid on Jun 10, 2024 going ex on May 15, 2024
May 16, 2024
Jun 10, 2024
May 15, 2024
Dec 08, 2023
LLY.NB Interim Cash Dividend of gross USD 1.3 paid on Mar 08, 2024 going ex on Feb 14, 2024
Feb 15, 2024
Mar 08, 2024
Feb 14, 2024
Nov 01, 2023
LLY.NB Final Cash Dividend of gross USD 1.13 paid on Dec 08, 2023 going ex on Nov 14, 2023
Nov 15, 2023
Dec 08, 2023
Nov 14, 2023
Jun 26, 2023
LLY.NB Interim Cash Dividend of gross USD 1.13 paid on Sep 08, 2023 going ex on Aug 14, 2023
Aug 15, 2023
Sep 08, 2023
Aug 14, 2023
May 01, 2023
LLY.NB Interim Cash Dividend of gross USD 1.13 paid on Jun 09, 2023 going ex on May 12, 2023
May 15, 2023
Jun 09, 2023
May 12, 2023
Dec 12, 2022
LLY.NB Interim Cash Dividend of gross USD 1.13 paid on Mar 10, 2023 going ex on Feb 14, 2023
Feb 15, 2023
Mar 10, 2023
Feb 14, 2023
Oct 17, 2022
LLY.NB Final Cash Dividend of gross USD 0.98 paid on Dec 09, 2022 going ex on Nov 14, 2022
Nov 15, 2022
Dec 09, 2022
Nov 14, 2022
查看更多
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
